Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:GXYLT2-VAV1

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: GXYLT2-VAV1
	FusionPDB ID: 35419
	FusionGDB2.0 ID: 35419
		Hgene	Tgene
	Gene symbol	GXYLT2	VAV1
	Gene ID	727936	7409
	Gene name	glucoside xylosyltransferase 2	vav guanine nucleotide exchange factor 1
	Synonyms	GLT8D4	VAV
	Cytomap	3p13	19p13.3
	Type of gene	protein-coding	protein-coding
	Description	glucoside xylosyltransferase 2glycosyltransferase 8 domain containing 4glycosyltransferase 8 domain-containing protein 4	proto-oncogene vavvav 1 guanine nucleotide exchange factorvav 1 oncogene
	Modification date	20200313	20200313
	UniProtAcc	A0PJZ3 Main function of 5'-partner protein: FUNCTION: Glycosyltransferase which elongates the O-linked glucose attached to EGF-like repeats in the extracellular domain of Notch proteins by catalyzing the addition of xylose. {ECO:0000269\|PubMed:19940119}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000389617,	ENST00000304076, ENST00000539284, ENST00000596764, ENST00000599806, ENST00000602142,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	7 X 5 X 5=175	10 X 11 X 8=880
	# samples	7	12
	** MAII score	log2(7/175*10)=-1.32192809488736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(12/880*10)=-2.87446911791614 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: GXYLT2 [Title/Abstract] AND VAV1 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: GXYLT2 [Title/Abstract] AND VAV1 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	GXYLT2(72971486)-VAV1(6821633), # samples:1
Anticipated loss of major functional domain due to fusion event.	GXYLT2-VAV1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. GXYLT2-VAV1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. GXYLT2-VAV1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. GXYLT2-VAV1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	GXYLT2	GO:0016266	O-glycan processing	19940119

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr3:72971486/chr19:6821633)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across GXYLT2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across VAV1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000389617	GXYLT2	chr3	72971486	-	ENST00000304076	VAV1	chr19	6821633	+	3171	761	80	2911	943
ENST00000389617	GXYLT2	chr3	72971486	-	ENST00000602142	VAV1	chr19	6821633	+	2978	761	80	2977	966
ENST00000389617	GXYLT2	chr3	72971486	-	ENST00000596764	VAV1	chr19	6821633	+	3135	761	80	2881	933
ENST00000389617	GXYLT2	chr3	72971486	-	ENST00000539284	VAV1	chr19	6821633	+	3135	761	80	2881	933
ENST00000389617	GXYLT2	chr3	72971486	-	ENST00000599806	VAV1	chr19	6821633	+	3237	761	80	2977	965

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000389617	ENST00000304076	GXYLT2	chr3	72971486	-	VAV1	chr19	6821633	+	0.009607511	0.99039257
ENST00000389617	ENST00000602142	GXYLT2	chr3	72971486	-	VAV1	chr19	6821633	+	0.008481337	0.9915187
ENST00000389617	ENST00000596764	GXYLT2	chr3	72971486	-	VAV1	chr19	6821633	+	0.007745437	0.9922545
ENST00000389617	ENST00000539284	GXYLT2	chr3	72971486	-	VAV1	chr19	6821633	+	0.007745437	0.9922545
ENST00000389617	ENST00000599806	GXYLT2	chr3	72971486	-	VAV1	chr19	6821633	+	0.007004947	0.9929951

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for GXYLT2-VAV1

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
GXYLT2	chr3	72971486	VAV1	chr19	6821633	761	35	PPRRTMKLRSKAAALLLLALAALLLA

Top

Potential FusionNeoAntigen Information of GXYLT2-VAV1 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

GXYLT2-VAV1_72971486_6821633.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B14:01	LRSKAAAL	0.9955	0.8604	7	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B14:02	LRSKAAAL	0.9955	0.8604	7	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B27:07	LRSKAAALL	0.9984	0.7169	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B27:04	LRSKAAALL	0.9977	0.7538	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B39:01	SKAAALLLL	0.9956	0.7887	9	18
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B15:17	RSKAAALLL	0.9955	0.9027	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-A30:08	RSKAAALLL	0.994	0.7632	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B08:09	KLRSKAAAL	0.994	0.6513	6	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B15:16	RSKAAALLL	0.9931	0.895	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B58:02	RSKAAALLL	0.993	0.8668	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B57:03	RSKAAALLL	0.9892	0.9711	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B39:24	LRSKAAALL	0.9792	0.5733	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-A30:08	KLRSKAAAL	0.968	0.8072	6	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B39:06	MKLRSKAAA	0.9262	0.8089	5	14
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-A02:13	KLRSKAAAL	0.9233	0.7177	6	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B38:02	LRSKAAALL	0.7173	0.964	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B48:01	SKAAALLLL	0.6818	0.6405	9	18
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B08:01	MKLRSKAAAL	0.9877	0.8823	5	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B08:01	TMKLRSKAAAL	0.9994	0.8729	4	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B39:12	LRSKAAAL	0.99	0.8232	7	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C15:04	RSKAAALLL	0.9992	0.7979	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C03:08	AAALLLLAL	0.9985	0.9206	11	20
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C03:19	AAALLLLAL	0.9981	0.9928	11	20
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C15:06	RSKAAALLL	0.9976	0.8139	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C03:08	RSKAAALLL	0.9906	0.8869	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C07:05	LRSKAAALL	0.9888	0.9563	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C07:95	LRSKAAALL	0.9874	0.6857	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C07:27	LRSKAAALL	0.9698	0.9396	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C02:06	AAALLLLAL	0.9556	0.9843	11	20
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C07:29	LRSKAAALL	0.953	0.9277	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B39:12	LRSKAAALL	0.9511	0.8678	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C07:13	LRSKAAALL	0.9373	0.9393	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B15:04	KLRSKAAAL	0.9344	0.9477	6	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B15:07	KLRSKAAAL	0.9119	0.8232	6	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C02:06	RSKAAALLL	0.8854	0.9056	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C07:19	LRSKAAALL	0.8593	0.7998	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C12:16	LRSKAAALL	0.0632	0.962	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C15:02	KAAALLLL	0.9999	0.8134	10	18
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C15:09	RSKAAALLL	0.9992	0.7979	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B27:06	LRSKAAALL	0.9985	0.8128	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C03:04	AAALLLLAL	0.9985	0.9859	11	20
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C03:03	AAALLLLAL	0.9985	0.9859	11	20
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C15:05	RSKAAALLL	0.9979	0.8421	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B27:08	LRSKAAALL	0.9978	0.7706	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B27:09	LRSKAAALL	0.9975	0.858	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C15:02	RSKAAALLL	0.9975	0.7812	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C03:05	AAALLLLAL	0.9972	0.9345	11	20
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C03:17	AAALLLLAL	0.9967	0.9677	11	20
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B39:02	SKAAALLLL	0.9964	0.8588	9	18
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B58:06	RSKAAALLL	0.9946	0.8271	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-A30:01	RSKAAALLL	0.9944	0.8761	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-A02:03	KLRSKAAAL	0.9903	0.7058	6	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C07:01	LRSKAAALL	0.9891	0.6839	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-A32:01	RSKAAALLL	0.9875	0.9081	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C16:02	RSKAAALLL	0.9839	0.9807	8	17
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C06:08	LRSKAAALL	0.9651	0.9861	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B15:35	KLRSKAAAL	0.9101	0.9273	6	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B15:73	KLRSKAAAL	0.9068	0.9462	6	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B35:13	AAALLLLAL	0.8984	0.8863	11	20
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B39:31	LRSKAAALL	0.8975	0.8642	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C17:01	AAALLLLAL	0.8731	0.9856	11	20
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C07:22	LRSKAAALL	0.8638	0.6754	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C06:08	SKAAALLLL	0.7601	0.9364	9	18
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B15:30	KLRSKAAAL	0.683	0.9107	6	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B08:12	KLRSKAAAL	0.6823	0.6027	6	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C06:17	LRSKAAALL	0.0726	0.9894	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-C06:02	LRSKAAALL	0.0726	0.9894	7	16
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B08:18	MKLRSKAAAL	0.9877	0.8823	5	15
GXYLT2-VAV1	chr3	72971486	chr19	6821633	761	HLA-B08:18	TMKLRSKAAAL	0.9994	0.8729	4	15

Top

Potential FusionNeoAntigen Information of GXYLT2-VAV1 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of GXYLT2-VAV1

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
4403	KLRSKAAALLLLAL	GXYLT2	VAV1	chr3	72971486	chr19	6821633	761

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of GXYLT2-VAV1

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	4403	KLRSKAAALLLLAL	-7.9962	-8.1096
HLA-B14:02	3BVN	4403	KLRSKAAALLLLAL	-5.70842	-6.74372
HLA-B52:01	3W39	4403	KLRSKAAALLLLAL	-6.83737	-6.95077
HLA-B52:01	3W39	4403	KLRSKAAALLLLAL	-4.4836	-5.5189
HLA-A11:01	4UQ2	4403	KLRSKAAALLLLAL	-10.0067	-10.1201
HLA-A11:01	4UQ2	4403	KLRSKAAALLLLAL	-9.03915	-10.0745
HLA-A24:02	5HGA	4403	KLRSKAAALLLLAL	-6.56204	-6.67544
HLA-A24:02	5HGA	4403	KLRSKAAALLLLAL	-5.42271	-6.45801
HLA-B44:05	3DX8	4403	KLRSKAAALLLLAL	-7.85648	-8.89178
HLA-B44:05	3DX8	4403	KLRSKAAALLLLAL	-5.3978	-5.5112
HLA-A02:01	6TDR	4403	KLRSKAAALLLLAL	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of GXYLT2-VAV1

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
GXYLT2-VAV1	chr3	72971486	chr19	6821633	10	18	KAAALLLL	TTTCTTCCGGTCATCTACACCCTG
GXYLT2-VAV1	chr3	72971486	chr19	6821633	11	20	AAALLLLAL	CTTCCGGTCATCTACACCCTGTCTGCT
GXYLT2-VAV1	chr3	72971486	chr19	6821633	4	15	TMKLRSKAAAL	TGTGCTGCCCAGAGACTCTTTCTTCCGGTCATC
GXYLT2-VAV1	chr3	72971486	chr19	6821633	5	14	MKLRSKAAA	GCTGCCCAGAGACTCTTTCTTCCGGTC
GXYLT2-VAV1	chr3	72971486	chr19	6821633	5	15	MKLRSKAAAL	GCTGCCCAGAGACTCTTTCTTCCGGTCATC
GXYLT2-VAV1	chr3	72971486	chr19	6821633	6	15	KLRSKAAAL	GCCCAGAGACTCTTTCTTCCGGTCATC
GXYLT2-VAV1	chr3	72971486	chr19	6821633	7	15	LRSKAAAL	CAGAGACTCTTTCTTCCGGTCATC
GXYLT2-VAV1	chr3	72971486	chr19	6821633	7	16	LRSKAAALL	CAGAGACTCTTTCTTCCGGTCATCTAC
GXYLT2-VAV1	chr3	72971486	chr19	6821633	8	17	RSKAAALLL	AGACTCTTTCTTCCGGTCATCTACACC
GXYLT2-VAV1	chr3	72971486	chr19	6821633	9	18	SKAAALLLL	CTCTTTCTTCCGGTCATCTACACCCTG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of GXYLT2-VAV1

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
LUAD	GXYLT2-VAV1	chr3	72971486	ENST00000389617	chr19	6821633	ENST00000304076	TCGA-97-A4M5-01A

Top

Potential target of CAR-T therapy development for GXYLT2-VAV1

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

GXYLT2

chr3:72971486

chr19:6821633

ENST00000389617

5_25

200

444.0

Transmembrane

Helical%3B Signal-anchor for type II membrane protein

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to GXYLT2-VAV1

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to GXYLT2-VAV1

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)